Business Context and Reporting Period
Company: Caris Life Sciences, Inc. (CAI)
Filing Type: Form 8-K (Current Report)
Date of Report: January 12, 2026
Reporting Period: Preliminary unaudited financial results for the quarter and full year ended December 31, 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This 8-K serves as a notification that preliminary results were announced via a press release (Exhibit 99.1), which is incorporated by reference solely for Item 2.02 disclosure purposes. No financial data is embedded directly within the body of this report.
Material Changes
The filing does not detail specific material changes versus prior periods. It references the issuance of a press release containing preliminary results for the period ended December 31, 2025, but does not summarize the variances or trends within this document.
Guidance, Outlook, and Risks
- Conference Presentation: The Company will present materials at the 2026 J.P. Morgan Healthcare Conference on January 12, 2026. These materials will be posted to the investor relations website.
- Incorporation Status: The conference presentation materials are explicitly not incorporated into this Current Report on Form 8-K.
- Legal Disclaimer: Information in this report, including the press release, is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section, except as expressly set forth in other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release issued January 12, 2026) for the actual preliminary financial figures for Q4 and FY 2025.
- Access the Investor Relations website for the 2026 J.P. Morgan Healthcare Conference presentation materials.
- Verify the unaudited nature of the reported results as stated in the filing.
- Confirm the Emerging Growth Company status indicated in the filing header.